Digirad, a provider of in-office nuclear cardiology imaging and ultrasound services, has inked an exclusive international distribution agreement with Dilon Diagnostics, a developer of molecular breast imaging equipment, covering distribution of Digirad products to most countries outside the US.
Dilon will now distribute Digirad’s nuclear imaging camera line, including the ergo large field-of-view general-purpose gamma camera, the Cardius x.act triple-head cardiac dedicated SPECT camera with Digirad’s volume CT (VCT) attenuation correction technology, and the Cardius XPO dedicated cardiac SPECT camera.
Digirad president and CEO Matthew G Molchan noted the company is pleased with this enhanced relationship with Dilon and the opportunity to further expand its product reach beyond the US.
"We continue to believe that our nuclear imaging cameras, with their solid-state design and technology, are well suited to meet the needs of the international market and we are very excited to partner with Dilon to distribute our cameras around the world," Molchan added.
Dilon Diagnostics chairman and CEO Robert G Moussa noted the company is pleased to expand its already successful partnership with Digirad and is excited to broaden its offering of nuclear imaging products in the international marketplace.
"With the addition of the Digirad cameras to the existing Dilon product portfolio, we now have the ability to offer a full spectrum of diagnostic imaging solutions to our international customers and to afford the excellent range of Digirad’s nuclear imaging products access to our broad international network of customers," Moussa added.
Previously, Digirad and Dilon signed a technology development agreement in mid-2010.